Jiangsu Aidea Pharmaceutical Co., Ltd. (688488.SS)
CNY 8.87
(2.31%)
CNY 8.87
(2.31%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 186.94 Million CNY | 153.11% |
| 2022 | 73.85 Million CNY | 116.9% |
| 2021 | -437.11 Million CNY | -90.86% |
| 2020 | -229.01 Million CNY | -9286.97% |
| 2019 | 2.49 Million CNY | -87.28% |
| 2018 | 19.59 Million CNY | 119.9% |
| 2017 | -98.5 Million CNY | -1375.28% |
| 2016 | 7.72 Million CNY | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q3 | 154.84 Million CNY | -25.23% |
| 2024 Q1 | 218.7 Million CNY | 16.99% |
| 2024 Q2 | 207.08 Million CNY | -5.32% |
| 2023 Q3 | 63.1 Million CNY | -6.82% |
| 2023 Q4 | 186.94 Million CNY | 196.26% |
| 2023 FY | 186.94 Million CNY | 153.11% |
| 2023 Q1 | 26.46 Million CNY | -64.16% |
| 2023 Q2 | 67.71 Million CNY | 155.86% |
| 2022 Q4 | 73.85 Million CNY | 197.52% |
| 2022 Q3 | -75.73 Million CNY | 77.55% |
| 2022 Q2 | -337.32 Million CNY | -58.19% |
| 2022 FY | 73.85 Million CNY | 116.9% |
| 2022 Q1 | -213.23 Million CNY | 51.22% |
| 2021 Q4 | -437.11 Million CNY | -15.34% |
| 2021 Q3 | -378.97 Million CNY | 1.96% |
| 2021 Q2 | -386.53 Million CNY | -59.26% |
| 2021 Q1 | -242.7 Million CNY | 0.66% |
| 2021 FY | -437.11 Million CNY | -90.86% |
| 2020 Q2 | -30.78 Million CNY | -1768.07% |
| 2020 FY | -229.01 Million CNY | -9286.97% |
| 2020 Q4 | -244.3 Million CNY | 29.29% |
| 2020 Q3 | -345.5 Million CNY | -1022.28% |
| 2020 Q1 | -1.64 Million CNY | -166.11% |
| 2019 Q4 | 2.49 Million CNY | 0.0% |
| 2019 FY | 2.49 Million CNY | -87.28% |
| 2019 Q2 | 42.53 Million CNY | -47.74% |
| 2019 Q1 | 81.4 Million CNY | 0.0% |
| 2018 FY | 19.59 Million CNY | 119.9% |
| 2017 FY | -98.5 Million CNY | -1375.28% |
| 2016 FY | 7.72 Million CNY | 0.0% |